Cargando…

High dose, dose-intensive chemotherapy with doxorubicin and cyclophosphamide for the treatment of advanced breast cancer.

Eighteen patients with advanced breast cancer were commenced on treatment with high dose doxorubicin (100 mg m-2) or doxorubicin (100 mg m-2) and cyclophosphamide (500 mg m-2) at 2 weekly intervals. Three cycles of treatment were planned. rG-CSF was given subcutaneously for 10 days, starting 24 h af...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ferguson, J. E., Dodwell, D. J., Seymour, A. M., Richards, M. A., Howell, A.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1993
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968370/ https://www.ncbi.nlm.nih.gov/pubmed/7682432

Ejemplares similares

Dose intensity in cancer chemotherapy.
por: Dodwell, D. J., et al.
Publicado: (1990)

Long-term survival of advanced triple-negative breast cancers with a dose-intense cyclophosphamide/anthracycline neoadjuvant regimen
por: Giacchetti, S, et al.
Publicado: (2014)

Dose-intense weekly cyclophosphamide, methotrexate, 5-fluorouracil, vincristine and prednisolone (CMFP) in advanced breast cancer.
por: Cebon, J. S., et al.
Publicado: (1990)

Cyclophosphamide priming reduces intestinal damage in man following high dose melphalan chemotherapy.
por: Selby, P. J., et al.
Publicado: (1987)

High Dose Cyclophosphamide Treatment for Autoimmune Disorders
por: Brodsky, Robert A.
Publicado: (2002)

Pharmacogenetics of toxicity of 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients
por: Tecza, Karolina, et al.
Publicado: (2018)

High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy
por: de Jonge, M E, et al.
Publicado: (2006)

Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer
por: Foldi, Julia, et al.
Publicado: (2021)

Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer
por: Khan, O A, et al.
Publicado: (2011)

Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer
por: Khan, O A, et al.
Publicado: (2011)

Toxicity of the high-dose chemotherapy CTC regimen (cyclophosphamide, thiotepa, carboplatin): the Netherlands Cancer Institute experience
por: Schrama, J G, et al.
Publicado: (2003)

Genetic polymorphisms and response to 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients
por: Tecza, Karolina, et al.
Publicado: (2016)

NEPA efficacy and tolerability during (neo)adjuvant breast cancer chemotherapy with cyclophosphamide and doxorubicin
por: Yeo, Winnie, et al.
Publicado: (2022)

Automated chemotherapy compounding: Process optimization for the preparation of admixture containing high-dose of cyclophosphamide
por: Perego, Gianluca, et al.
Publicado: (2022)

Efficacy of up-front 5-fluorouracil-epidoxorubicin-cyclophosphamide (FEC) chemotherapy with an increased dose of epidoxorubicin in high-risk breast cancer patients.
por: van der Wall, E., et al.
Publicado: (1996)

Dose-Dense Epirubicin and Cyclophosphamide Followed by Docetaxel as Adjuvant Chemotherapy in Node-Positive Breast Cancer
por: Mirzaei, Hamid Reza, et al.
Publicado: (2013)

A study of ovarian cancer patients treated with dose-intensive chemotherapy supported with peripheral blood progenitor cells mobilised by filgrastim and cyclophosphamide.
por: Weaver, A., et al.
Publicado: (1996)

Neutrophil-guided dosing of anthracycline–cyclophosphamide-containing chemotherapy in patients with breast cancer: a feasibility study
por: Drooger, Jan C., et al.
Publicado: (2015)

Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide
por: Bray, J, et al.
Publicado: (2010)

High cumulative doxorubicin dose for advanced soft tissue sarcoma
por: Tian, Zhichao, et al.
Publicado: (2020)

Author Correction: Neoadjuvant durvalumab plus weekly nab-paclitaxel and dose-dense doxorubicin/cyclophosphamide in triple-negative breast cancer
por: Foldi, Julia, et al.
Publicado: (2022)

High-dose sequential epirubicin and cyclophosphamide with peripheral blood stem cell support for advanced breast cancer: results of a phase II study
por: Cottu, P H, et al.
Publicado: (2001)

Immunohistochemistry study of tumor vascular normalization and anti-angiogenic effects of sunitinib versus bevacizumab prior to dose-dense doxorubicin/cyclophosphamide chemotherapy in HER2-negative breast cancer
por: Yadav, Kritika, et al.
Publicado: (2021)

Increasing pacemaker lead impedance and pacing threshold after initiation of chemotherapy with doxorubicin and cyclophosphamide
por: Varela, Daniel L., et al.
Publicado: (2022)

High dose intensity combination chemotherapy for advanced epithelial ovarian carcinoma: results of a pilot study.
por: Sweetenham, J. W., et al.
Publicado: (1990)

Subclinical cardiotoxicity following adjuvant dose-escalated FEC, high-dose chemotherapy, or CMF in breast cancer
por: Erselcan, T, et al.
Publicado: (2000)

A Phase II Study to Evaluate the Safety and Efficacy of Pegteograstim in Korean Breast Cancer Patients Receiving Dose-Dense Doxorubicin/Cyclophosphamide
por: Kim, Gun Min, et al.
Publicado: (2019)

Treatment of advanced soft-tissue sarcomas using a combined strategy of high-dose ifosfamide, high-dose doxorubicin and salvage therapies
por: Leyvraz, S, et al.
Publicado: (2006)

Non-Pegylated Liposomal Doxorubicin-Cyclophosphamide in Sequential Regimens with Taxanes as Neoadjuvant Chemotherapy in Breast Cancer Patients
por: Vici, Patrizia, et al.
Publicado: (2014)

Prevention of acute deaths in mice after very high dose cyclophosphamide by divided dose schedule.
por: Evans, B. D., et al.
Publicado: (1984)

Effect of high-dose melphalan on marrow and intestinal epithelium in mice pretreated with cyclophosphamide.
por: Millar, J. L., et al.
Publicado: (1978)

Low-dose “metronomic chemotherapy” with oral cyclophosphamide and methotrexate in metastatic breast cancer: a case report of extraordinarily prolonged clinical benefit
por: Masci, G, et al.
Publicado: (2012)

Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer
por: Bernhard, J, et al.
Publicado: (2008)

Rare Case of Reversible Pulmonary Arterial Hypertension Secondary to Cyclophosphamide and Doxorubicin Chemotherapy
por: Javed, Aneeqa, et al.
Publicado: (2022)

High-dose paclitaxel in combination with doxorubicin, cyclophosphamide and peripheral blood progenitor cell rescue in patients with high-risk primary and responding metastatic breast carcinoma: toxicity profile, relationship to paclitaxel pharmacokinetics and short-term outcome
por: Somlo, G, et al.
Publicado: (2001)

SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer
por: Nahleh, Z. A., et al.
Publicado: (2016)

The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer.
por: Bronchud, M. H., et al.
Publicado: (1989)

Dose-dense paclitaxel plus carboplatin vs. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer
por: Li, Qing, et al.
Publicado: (2020)

Dose response of pegfilgrastim in Japanese breast cancer patients receiving six cycles of docetaxel, doxorubicin, and cyclophosphamide therapy: a randomized controlled trial
por: Masuda, Norikazu, et al.
Publicado: (2015)

Low-Dose Cyclophosphamide Associated With Hyponatremia and Hepatotoxicity
por: DeChiara, James R, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_nmnardvlc4ltjt19u1onl3a8ug